Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4+ T cells

Journal of Experimental Medicine

Volumn 188, Issue 10, 1998, Pages 1849-1857

  Chen, Wanjun ^a   Jin, Wenwen ^a   Wahl, Sharon M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

CD4+ T cells; Cytotoxic T lymphocyte associated antigen 4; Transforming growth factor

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE DELETION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL SURVIVAL; CROSS-LINKING REAGENTS; CYTOKINES; FLOW CYTOMETRY; IMMUNOCONJUGATES; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032538819     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.10.1849     Document Type: Article

References (52)

1. Allison, J.P., and M.F. Krummel. 1995. The Yin and Yang of T cell costimulation. Science. 270:932-933.
2. Walunas, T., C. Bakker, and J. Bluestone. 1996. CTLA4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183:2541-2550.
3. Bluestone, J. 1997. Is CTLA4 a master switch for peripheral T cell tolerance? J. Immunol. 158:1989-1993.
4. Thompson, C.B., and J.P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity. 7:445-450.
5. Linsley, P.S. 1995. Distinct role for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation. J. Exp. Med. 182:289-292.
6. Walunas, T., D. Lenschow, C. Bakker, P. Linsley, G. Freeman, J. Green, C. Thompson, and J. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:405-413.
7. Krummel, M., and J. Allison. 1995. CD28 and CTLA4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459-465.
8. Krummel, M., and J. Allison. 1996. CTLA4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533-2540.
9. Kearney, E., T. Walunas, R. Karr, P. Morton, D. Loh, J. Bluestone, and M. Jenkins. 1995. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA4. J. Immunol. 155:1032-1036.
10. Krummel, M., T. Sullivan, and J. Allison. 1996. Superantigen responses and co-stimulation: CD28 and CTLA4 have opposing effects on T cell expansion in vitro and in vivo. Int. Immunol. 8:519-523.
11. Leach, D., M. Krummel, and J. Allison. 1996. Enhancement of antitumor immunity by CTLA4 blockade. Science. 271: 1734-1736.
12. Karandikar, N., C. Vanderlugt, T. Walunas, S. Miller, and J. Bluestone. 1996. CTLA4: a negative regulator of autoimmune disease. J. Exp. Med. 184:783-788.
13. Waterhouse, P., J. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. Lee, C. Thompson, H. Griesser, and T.W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 270:985-988.
14. Tivol, E., F. Borriello, A. Schweitzer, W. Lynch, J. Bluestone, and A. Sharpe. 1995. Loss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction. Immunity. 3:541-547.
15. Gribben, J.G., G.J. Freeman, V.A. Boussiotis, P. Rennert, C.L. Jellis, E. Greenfield, M. Barber, V.A. Restivo, Jr., X. Ke, G.S. Gray, and L. Nadler. 1995. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA. 92:811-815.
16. Waterhouse, P., L.E. Marengere, H.-W. Mittrucker, and T. W. Mak. 1996. CTLA-4, a negative regulator of T-lymphocyte activation. Immunol. Rev. 153:183-204.
17. Massague, J. 1990. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 6:597-641.
18. McCartney-Francis, N.L., and S.M. Wahl. 1994. Transforming growth factor β: a matter of life and death. J. Leukocyte Biol. 55:401-409.
19. Wahl, S.M. 1994. Transforming growth factor: the good, the bad, and the ugly. J. Exp. Med. 180:1587-1590.
20. Kehrl, J.H., L.M. Wakefield, A.B. Roberts, S. Jakowlew, M. Alvarez-Mon, R. Derynck, M.B. Sporn, and A.S. Fauci. 1986. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163:1037-1050.
21. Wahl, S.M., D.A. Hunt, H.L. Wong, S. Dougherty, N. Mc-Cartney-Francis, L.M. Wahl, L. Ellingsworth, J.A. Schmidt, G. Hall, A.B. Roberts, and M.B. Sporn. 1988. Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J. Immunol. 140:3026-3032.
22. Barral-Netto, M., A. Barral, C.E. Rownell, Y.A.W. Skeiky, L.R. Ellingsworth, D.R. Twardzik, and S.G. Reed. 1992. Transforming growth factor-β in leishmanial infection: a parasite mechanism. Science. 257:545-548.
23. Brandes, M.E., J.B. Allen, Y. Ogawa, and S.M. Wahl. 1991. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J. Exp. Med. 87:1108-1113.
24. Kuruvilla, A.P., R. Shah, G.M. Hochwald, H.D. Liggitt, M.A. Palladono, and G.J. Thorbecke. 1991. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA. 88:2918-2921.
25. Chen, Y., V.K. Kuchroo, J. Inobe, D.A. Hafler, and H.L. Weiner. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1237-1240.
26. Swain, S.L., L.G. Huston, S. Tonkonogy, and A. Weinberg. 1991. Transforming growth factor-β and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol. 147:2991-3000.
27. Weinberg, A.D., R. Whitham, S.L. Swain, W.J. Morrison, G. Wyrick, C. Hoy, A.A. Vandenbark, and H. Offner. 1992. Transforming growth factor-β enhances the in vivo effector function and memory phenotype of antigen-specific T helper cells in experimental autoimmune encephalomyelitis. J. Immunol. 148:2109-2117.
28. Cerwenka, A., D. Bevec, O. Majdic, W. Knapp, and W. Holter. 1994. TGF-β1 is a potent inducer of human effector T cells. J. Immunol. 153:4367-4377.
29. Shull, M.M., I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Diebold, M. Yin, R. Allen, C. Sidman, B. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 359:693-699.
30. Kulkarni, A.B., C.-H. Huh, D. Becker, A. Gerser, M. Lyght, K.C. Flanders, A.B. Roberts, M.B. Sporn, J.M. Ward, and S. Karlsson. 1993. Transforming growth factor-β null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA. 90:770-774.
31. Christ, M., N.L. McCartney-Francis, A.B. Kulkarni, J.M. Ward, D.E. Mizel, C.L. Mackall, R.E. Gress, K.L. Hines, H. Tian, S. Karlsson, and S.M. Wahl. 1994. Immune dysregulation in TGF-β1-deficient mice. J. Immunol. 153:1936-1946.
32. Seder, R.A., T. Marth, M.C. Sieve, W. Strober, J.J. Letterio, A.B. Roberts, and B. Kelsall. 1998. Factors involved in the differentiation of TGF-β-producing cells from naive CD4+ T cells: IL-4 and IFN-γ have opposing effects, while TGF-β positively regulates its own production. J. Immunol. 160: 5719-5728.
33. lo thymocytes in vivo. Science. 250:1720-1723.
34. Chen, W.J., S. Issazadeh, M.H. Sayegh, and S.J. Khoury. 1997. In vivo mechanisms of acquired thymic tolerance. Cell. Immunol. 179:165-173.
35. Schmid, I., C.H. Uittenbogaart, B. Keld, and J.V. Giorgi. 1994. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J. Immunol. Methods. 170:145-157.
36. Schwartz, R.H. 1989. Acquisition of immunologic self-tolerance. Cell. 57:1073-1081.
37. Dubley, C., M. Croft, and S. Swain. 1996. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J. Immunol. 157:3280-3289.
38. Swain, S.L. 1994. Generation and in vivo persistence of polarized Th1 and Th2 memory cells. Immunity. 1:543-552.
39. McCartney-Francis, N.L., M. Frazier-Jessen, and S.M. Wahl. 1998. TGF-β: a balancing act. Im. Rev. Immunol. 16:553-580.
40. Massague, J. 1996. TGFβ signaling: receptors, transducers, and Mad proteins. Cell. 85:947-950.
41. Hannon, G.J., and D. Beach. 1994. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature. 371: 257-261.
42. Johns, L.D., K.C. Flanders, G.E. Ranges, and S. Sriram. 1991. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. J. Immunol. 147:1792-1796.
43. Racke, M.K., S. Dhib-Jalbut, B. Cannella, P.S. Albert, C.S. Raine, and D.E. McFarlin. 1991. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β. J. Immunol. 146:3012-3017.
44. Chen, W.J., W. Jin, M. Cook, H.L. Weiner, and S.M. Wahl. 1998. Oral delivery of group A streptococcal cell walls augments circulating TGF-β and suppresses SCW arthritis. J. Immunol. In press.
45. Fakhrai, H., O. Dorigo, D. Shawler, H. Lin, D. Mercola, K. Black, I. Royston, and R. Sobol. 1996. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA. 93: 2909-2914.
46. Andalib, A., J. Lawry, S. Ali, A. Murry, K. Sisley, P. Silcocks, M. Herlyn, and R. Rees. 1997. Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumor tissues. Melanoma Res. 7:32-34.
47. Ito, N., S. Kawata, H. Tsushima, S. Tamura, S. Kiso, S. Takami, T. Lgura, M. Monnden, and Y. Matsuzawa. 1997. Increased circulating transforming growth factor beta1 in a patient with giant hepatic hemangioma: possible contribution to an impaired immune function. Hepatology. 25:93-96.
48. Knoefel, B., K. Nuske, T. Steiner, K. Junker, H. Kosmehl, K. Rebstock, D. Reinhold, and U. Junker. 1997. Renal cell carcinomas produce IL-6, IL-10, IL-11 and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J. Interferon Cytokine Res. 17:95-102.
49. Perez, V.L., L.V. Parijs, A. Biuckians, X.X. Zheng, T.B. Strom, and A.K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 6: 411-417
50. Arteaga, C.L., R.J.J. Coffey, T.C. Dugger, C.M. Mc-Cutchen, H.L. Moses, and R.M. Lyons. 1990. Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies: evidence for negative autocrine regulation by transforming growth factor β. Cell Growth Differ. 1:367-374.
51. Wu, S., D. Theodorescu, R. Kerbel, J.K.V. Willson, K.M. Mulder, L.E. Humphrey, and M.G. Brattain. 1992. TGF-beta1 is an autocrine negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an anti-sense expression vector. J. Cell Biol. 116:187-196.
52. Click, A.B., M.M. Lee, N. Darwiche, A.B. Kulkarni, S. Karlsson, and S.H. Yuspa. 1994. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev. 8:2429-2440.